313 related articles for article (PubMed ID: 30281202)
21. Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis.
Verspohl SH; Holderried T; Behning C; Brossart P; Schäfer VS
Ther Adv Musculoskelet Dis; 2021; 13():1759720X211006963. PubMed ID: 33912248
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series.
Kim ST; Tayar J; Trinh VA; Suarez-Almazor M; Garcia S; Hwu P; Johnson DH; Uemura M; Diab A
Ann Rheum Dis; 2017 Dec; 76(12):2061-2064. PubMed ID: 28830882
[TBL] [Abstract][Full Text] [Related]
23. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
Tison A; Quéré G; Misery L; Funck-Brentano E; Danlos FX; Routier E; Robert C; Loriot Y; Lambotte O; Bonniaud B; Scalbert C; Maanaoui S; Lesimple T; Martinez S; Marcq M; Chouaid C; Dubos C; Brunet-Possenti F; Stavris C; Chiche L; Beneton N; Mansard S; Guisier F; Doubre H; Skowron F; Aubin F; Zehou O; Roge C; Lambert M; Pham-Ledard A; Beylot-Barry M; Veillon R; Kramkimel N; Giacchero D; De Quatrebarbes J; Michel C; Auliac JB; Gonzales G; Decroisette C; Le Garff G; Carpiuc I; Vallerand H; Nowak E; Cornec D; Kostine M;
Arthritis Rheumatol; 2019 Dec; 71(12):2100-2111. PubMed ID: 31379105
[TBL] [Abstract][Full Text] [Related]
24. Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy.
Bitton K; Michot JM; Barreau E; Lambotte O; Haigh O; Marabelle A; Voisin AL; Mateus C; Rémond AL; Couret C; Champiat S; Labetoulle M; Rousseau A
Am J Ophthalmol; 2019 Jun; 202():109-117. PubMed ID: 30772350
[TBL] [Abstract][Full Text] [Related]
25. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity.
Calabrese C; Kirchner E; Kontzias A; Velcheti V; Calabrese LH
RMD Open; 2017; 3(1):e000412. PubMed ID: 28405474
[TBL] [Abstract][Full Text] [Related]
26. Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy.
Liew DFL; Leung JLY; Liu B; Cebon J; Frauman AG; Buchanan RRC
Int J Rheum Dis; 2019 Feb; 22(2):297-302. PubMed ID: 30549256
[TBL] [Abstract][Full Text] [Related]
27. Occurrence of Possible Rheumatologic Immune-Related Adverse Events (rh-irAEs) Associated with Immune Checkpoint Inhibitor (ICI) Therapy.
Anjohrin S; Sheahan A; Suruki R; Stark JL; Sloan VS
Rheumatol Ther; 2021 Dec; 8(4):1651-1659. PubMed ID: 34491550
[TBL] [Abstract][Full Text] [Related]
28. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen.
Cappelli LC; Brahmer JR; Forde PM; Le DT; Lipson EJ; Naidoo J; Zheng L; Bingham CO; Shah AA
Semin Arthritis Rheum; 2018 Dec; 48(3):553-557. PubMed ID: 29573850
[TBL] [Abstract][Full Text] [Related]
29. Severe neurologic complications of immune checkpoint inhibitors: a single-center review.
Mancone S; Lycan T; Ahmed T; Topaloglu U; Dothard A; Petty WJ; Strowd RE
J Neurol; 2018 Jul; 265(7):1636-1642. PubMed ID: 29761297
[TBL] [Abstract][Full Text] [Related]
30. Rheumatic Complications of Immune Checkpoint Inhibitors.
Ghosh N; Bass AR
Med Clin North Am; 2021 Mar; 105(2):227-245. PubMed ID: 33589099
[TBL] [Abstract][Full Text] [Related]
31. Treatment of immune checkpoint inhibitor-induced inflammatory arthritis.
Jeurling S; Cappelli LC
Curr Opin Rheumatol; 2020 May; 32(3):315-320. PubMed ID: 32168068
[TBL] [Abstract][Full Text] [Related]
32. Rheumatic immune-related adverse events from cancer immunotherapy.
Calabrese LH; Calabrese C; Cappelli LC
Nat Rev Rheumatol; 2018 Oct; 14(10):569-579. PubMed ID: 30171203
[TBL] [Abstract][Full Text] [Related]
33. Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors.
Feng S; Coward J; McCaffrey E; Coucher J; Kalokerinos P; O'Byrne K
J Thorac Oncol; 2017 Nov; 12(11):1626-1635. PubMed ID: 28843363
[TBL] [Abstract][Full Text] [Related]
34. Immune Checkpoint Inhibitor-induced Inflammatory Arthritis: Current Approaches to Management.
Singh N; Shahane A; Sparks JA; Bitoun S; Cappelli LC
Rheum Dis Clin North Am; 2024 May; 50(2):269-279. PubMed ID: 38670725
[TBL] [Abstract][Full Text] [Related]
35. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy.
Kostine M; Truchetet ME; Schaeverbeke T
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii68-vii74. PubMed ID: 31816082
[TBL] [Abstract][Full Text] [Related]
36. Immune Checkpoint Inhibitors-related Rheumatic Diseases: What Rheumatologist Should Know?
Gediz F; Kobak S
Curr Rheumatol Rev; 2019; 15(3):201-208. PubMed ID: 30659547
[TBL] [Abstract][Full Text] [Related]
37. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.
Abdel-Wahab N; Suarez-Almazor ME
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii40-vii48. PubMed ID: 31816084
[TBL] [Abstract][Full Text] [Related]
38. Impact of Non-steroidal Anti-inflammatory Drugs, Glucocorticoids, and Disease-Modifying Anti-Rheumatic Drugs on Cancer Response to Immune Checkpoint Inhibitor Therapy.
Chan KK; Bass AR
Rheum Dis Clin North Am; 2024 May; 50(2):337-357. PubMed ID: 38670731
[TBL] [Abstract][Full Text] [Related]
39. Treatment of rheumatic adverse events of cancer immunotherapy.
Reid P; Cappelli LC
Best Pract Res Clin Rheumatol; 2022 Dec; 36(4):101805. PubMed ID: 36539321
[TBL] [Abstract][Full Text] [Related]
40. Rheumatic complications in cancer patients treated with immune checkpoint inhibitors.
Lee KA; Kim HR; Yoon SY
Korean J Intern Med; 2019 Nov; 34(6):1197-1209. PubMed ID: 31014065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]